After allogeneic hematopoietic stem cell transplantation, clinicians now have a new standard for graft-versus-host disease ( GVHD ) prevention, according to study findings from phase III. Compared to the current gold standard, the new standard is more effective at preventing GVHD and has fewer side effects.
Study sets new standard for graft-versus-host disease prevention after stem cell transplant
